Corvus Pharmaceuticals, Inc. (CRVS) — Stock Score Summary

Corvus Pharmaceuticals, Inc. (CRVS) has a MoatMap StockRank of 35/100 based on Quality (40/100), Value (38/100), and Momentum (45/100) factor scores. The current signal is HOLD. Corvus is a clinical-stage biopharma company with binary clinical trial risks, making it a casualty of high CDMO pricing rather than a beneficiary.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel, first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The company's competitive moat is centered on its proprietary pipeline of small molecules and antibodies, most notably soquelitinib, a selective ITK inhibitor designed to reprogram T-cells to fight tumors. By targeting unique immunological pathways, Corvus aims to address significant unmet needs in oncology and immunology with highly differentiated therapeutic candidates.

Key Financial Metrics

Price$11.17
Market Cap$1.1B
P/E (Forward)-12.38
Price/Book4.10
Return on Equity-30.5%
Return on Invested Capital-69.6%
Debt/Equity0.35
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-23M

Corvus Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Corvus Pharmaceuticals, Inc.’s (CRVS) StockRank?
MoatMap’s StockRank for Corvus Pharmaceuticals, Inc. (CRVS) is 35/100, with a Hold signal. It is a composite of Quality (40), Value (38), and Momentum (45) factor ranks across MoatMap’s 19,000+ stock universe.
Does Corvus Pharmaceuticals, Inc. have an economic moat?
Corvus Pharmaceuticals, Inc. (CRVS) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Corvus Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Corvus Pharmaceuticals, Inc. (CRVS) is Hold, based on a StockRank of 35/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Corvus Pharmaceuticals, Inc. in?
Corvus Pharmaceuticals, Inc. (CRVS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCRVS deep dive reportAI ChampionsHow we score stocksSense-check another stock